Company: MDCXW
Filing Date: 2025-09-02
Form Type: 424B3
Source: 0001062993-25-015154
Chunk: 5

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-02
Form: 424B3
Chunk 5
---
,000 in annual cash compensation if he were appointed to serve as chair of any committee of the Board. In connection with his appointment, Mr. Mahaffy also received a grant of 25,000 stock options, which stock options will expire in five years, have an exercise price of $1.94, and will vest in equal quarterly instalments over the twelve months immediately following August 29, 2025.

There are no arrangements or understandings between Mr. Mahaffy and any other person pursuant to which Mr. Mahaffy was appointed as a director, there are no family relationships between Mr. Mahaffy and any director or other officer of the Company, and there are no transactions in which the Company is a party and in which Mr. Mahaffy has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

Item 8.01. Other Events.

On each of August 1, 2025, and on August 15, 2025, the Company, Antev and the Antev Vendors' representatives entered into Deeds of Variations which amended the Definitive Agreement (the "Deeds of Variation") to, among other things, provide that the Company has made a Tag Offer (as defined in the Deeds of Variation) to acquire all of the shares of Antev not held by the Antev Vendors. The Deeds of Variation are furnished as Exhibits 2.1 and 2.2 to this Current Report on Form 8-K.​

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

​

| Exhibit 
 No.     
 2.1*#   
 2.2*

#   |   | Description                                                                                                                                                                                                             
 Deed of Variation, dated August 1, 2025, relating to that certain Securities Exchange Agreement, dated June 29, 2025, by and between Antev Limited, the Antev Vendors' Representatives and Medicus Pharma Ltd.          
 Further Deed of Variation, dated August 15, 2025, relating to that certain Securities Exchange Agreement, dated June 29, 2025, by and between Antev Limited, the Antev Vendors' Representatives and Medicus Pharma Ltd. |
|:--------|:--|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 104     | ​ | Cover Page Interactive Data File (embedded within the inline XBRL document).                                                                                                                                            |

| * | Certain portions of this exhibit have been redacted